BIOMAT Database Logo BIOMAT Database Logo

2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. 1996

M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
Abbott Laboratories, Aging and Degenerative Diseases Research and Drug Analysis Department, Pharmaceutical Products Division, Abbott Park, Illinois 60064, USA.

We have discovered a novel class of endothelin (ET) receptor antagonists through pharmacophore analysis of the existing non-peptide ET antagonists. On the basis of this analysis, we determined that a pyrrolidine ring might replace the indian ring in SB 209670. The resultant compounds were readily prepared and amenable to extensive SAR studies. Thus a series of N-substituted trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)pyrroli din e-3- carboxylic acids (8) have been synthesized and evaluated for binding at ET(A) and ET(B) receptors. Compounds with N-acyl and simple N-alkyl substituents had weak activity. Compounds with N-alkyl substituents containing ethers, sulfoxides, or sulfones showed increased activity. Much improved activity resulted from compounds where the N-substituents were acetamides. Compound 17u (A-127722) with the N,N-dibutylacetamide substituent is the best of the series. It has an IC(50)=0.36 nM for inhibition of ET-1 radioligand binding at the ET(A) receptor, with a 1000-fold selectivity for the ET(A) vs the ET(B) receptor. It is also a potent inhibitor (IC(50)=0.16 nM) of phosphoinositol hydrolysis stimulated by ET-1, and it antagonized the ET-1-induced contraction of the rabbit aorta with a pA(2)=9.20. The compound has 70% oral bioavailability in rats.

UI MeSH Term Description Entries
D008297 Male Males
D010716 Phosphatidylinositols Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to the hexahydroxy alcohol, myo-inositol. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid, myo-inositol, and 2 moles of fatty acids. Inositide Phospholipid,Inositol Phosphoglyceride,Inositol Phosphoglycerides,Inositol Phospholipid,Phosphoinositide,Phosphoinositides,PtdIns,Inositide Phospholipids,Inositol Phospholipids,Phosphatidyl Inositol,Phosphatidylinositol,Inositol, Phosphatidyl,Phosphoglyceride, Inositol,Phosphoglycerides, Inositol,Phospholipid, Inositide,Phospholipid, Inositol,Phospholipids, Inositide,Phospholipids, Inositol
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000077868 Atrasentan A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES. (11C)ABT-627,2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid,A 127722,A 147627,A-127722,A-127722.5,A-147627,ABT 627,ABT-627,Atrasentan Hydrochloride,Xinlay,A 127722.5,A127722,A127722.5,A147627,ABT627
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001011 Aorta The main trunk of the systemic arteries. Aortas
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists.
May 1994, Journal of medicinal chemistry,
M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
Endothelin antagonists: discovery of EMD 122946, a highly potent and orally active ETA selective antagonist.
July 1998, Bioorganic & medicinal chemistry letters,
M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor.
January 1992, Life sciences,
M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.
April 1995, Journal of medicinal chemistry,
M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists.
September 1992, Journal of medicinal chemistry,
M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
Cyclic hexapeptide endothelin receptor antagonists highly potent for both receptor subtypes ETA and ETB.
May 1994, Biochemical and biophysical research communications,
M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
Potent, selective MCH-1 receptor antagonists.
February 2008, Bioorganic & medicinal chemistry letters,
M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis.
April 1992, European journal of pharmacology,
M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.
August 2000, Journal of medicinal chemistry,
M Winn, and T W von Geldern, and T J Opgenorth, and H S Jae, and A S Tasker, and S A Boyd, and J A Kester, and R A Mantei, and R Bal, and B K Sorensen, and J R Wu-Wong, and W J Chiou, and D B Dixon, and E I Novosad, and L Hernandez, and K C Marsh
Isoindolines: a new series of potent and selective endothelin-A receptor antagonists.
July 2001, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!